SpringerLink
Log in

Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study

  • Original Article
  • Published:
Pediatric Surgery International Aims and scope Submit manuscript

Abstract

Aims

This pilot study aims to assess the short-term efficacy and safety of mirabegron in valve bladder, an important cause of persistent hydronephrosis after successful treatment of posterior urethral valves (PUV).

Methods

Twenty-two patients with early valve bladder (no residual PUV; persistent hydronephrosis, wetting and urodynamic evidence of detrusor overactivity) were included. Three subjective parameters: frequency, wetting episodes; patient perception of bladder condition score (PPBC) and four objective parameters: uroflow index (UI = Qave/Qmax), voided volume (VV = voided volume/ expected bladder capacity), maximum filling pressure (P det-max) and society of fetal urology (SFU) hydronephrosis grading were analysed pre- and post-3-month treatment with mirabegron (0.5–1 mg/kg/day). All patients were observed for heart rate, BP, ECG changes during therapy.

Results

There was significant reduction (p = 0.001) in mean frequency (pre 15; post 10), wetting episodes (pre 5; post 2) and PPBC (pre 4; post 3). There was significant improvement (p = 0.01) in mean UI (pre 0.3; post 0.5), VV (pre 0.54; post 0.72), Pdet-max (pre 42; post 25) and hydronephrosis grade (pre 3.5; post 2.2). There were no significant side effects.

Conclusion

This pilot study establishes short-term efficacy and safety of mirabegron in valve bladder with overactivity. Further larger long-term studies are warranted.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

References

  1. Jaureguizar E, López-Pereira P, Martinez-Urrutia MJ (2002) The valve bladder: Etiology and outcome. Curr Urol Rep 3:115–120. https://doi.org/10.1007/s11934-002-0021-8

    Article  PubMed  Google Scholar 

  2. Glassberg KI (2001) The valve bladder syndrome: 20 years later. J Urol 166:1406–1414

    Article  CAS  Google Scholar 

  3. Blais A-S, Nadeau G, Moore K, Genois L, Bolduc S (2016) Prospective pilot study of mirabegron in pediatric patients with overactive bladder. Eur Urol 70:9–13. https://doi.org/10.1016/j.eururo.2016.02.007

    Article  PubMed  Google Scholar 

  4. Fryer S, Nicoara C, Dobson E, Griffiths M, McAndrew HF, Kenny SE et al (2020) Effectiveness and tolerability of mirabegron in children with overactive bladder: a retrospective pilot study. J Pediatr Surg 55:316–318. https://doi.org/10.1016/j.jpedsurg.2019.10.044

    Article  PubMed  Google Scholar 

  5. Sager C, Sanmartino M, Burek C, Gomez YR, Vazquez Patiño M, Weller S et al (2020) Efficacy and safety of mirabegron as adjuvant treatment in children with refractory neurogenic bladder dysfunction. J Pediatr Urol. https://doi.org/10.1016/j.jpurol.2020.07.020

    Article  PubMed  Google Scholar 

  6. Park JS, Lee YS, Lee CN, Kim SH, Kim SW, Han SW (2019) Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study. World J Urol 37:1665–1670. https://doi.org/10.1007/s00345-018-2576-0

    Article  CAS  PubMed  Google Scholar 

  7. Futyma K, Nowakowski Ł, Bogusiewicz M, Ziętek A, Wieczorek AP, Rechberger T (2017) Use of uroflow parameters in diagnosing an overactive bladder-Back to the drawing board. Neurourol Urodyn 36:198–202. https://doi.org/10.1002/nau.22898

    Article  PubMed  Google Scholar 

  8. Niyogi A, Lumpkins K, Robb A, McCarthy L (2017) Cystometrogram appearance in PUV is reliably quantified by the shape, wall, reflux and diverticuli (SWRD) score, and presages the need for intervention. J Pediatr Urol 13:265.e1-265.e6. https://doi.org/10.1016/j.jpurol.2016.12.005

    Article  CAS  Google Scholar 

  9. Bauer SB, Dieppa RA, Labib KK, Retik AB (1979) The bladder in boys with posterior urethral valves: a urodynamic assessment. J Urol 121:769–773. https://doi.org/10.1016/S0022-5347(17)56985-2

    Article  CAS  PubMed  Google Scholar 

  10. Duckett JW (1997) Are ‘valve bladders’ congenital or iatrogenic? Br J Urol 79:271–275. https://doi.org/10.1046/j.1464-410X.1997.26922.x

    Article  CAS  PubMed  Google Scholar 

  11. Mitchell ME, Close CE (1996) Early primary valve ablation for posterior urethral valves. Semin Pediatr Surg 5:66–71

    CAS  PubMed  Google Scholar 

  12. Koff SA, Mutabagani KH, Jayanthi VR (2002) The valve bladder syndrome: pathophysiology and treatment with nocturnal bladder emptying. J Urol 167:291–297. https://doi.org/10.1016/S0022-5347(05)65453-5

    Article  PubMed  Google Scholar 

  13. Abraham MK, Nasir ARA, Sudarsanan B, Puzhankara R, Kedari PM, Unnithan GR et al (2009) Role of alpha adrenergic blocker in the management of posterior urethral valves. Pediatr Surg Int 25:1113–1115. https://doi.org/10.1007/s00383-009-2469-9

    Article  PubMed  Google Scholar 

  14. Casey JT, Hagerty JA, Maizels M, Chaviano AH, Yerkes E, Lindgren BW et al (2012) Early administration of oxybutynin improves bladder function and clinical outcomes in newborns with posterior urethral valves. J Urol 188:1516–1520. https://doi.org/10.1016/j.juro.2012.03.068

    Article  CAS  PubMed  Google Scholar 

  15. Bolduc S, Moore K, Lebel S, Lamontagne P, Hamel M (2009) Double anticholinergic therapy for refractory overactive bladder. J Urol 182:2033–2039. https://doi.org/10.1016/j.juro.2009.05.099

    Article  CAS  PubMed  Google Scholar 

  16. Morin F, Blais A-S, Nadeau G, Moore K, Genois L, Bolduc S (2017) Dual therapy for refractory overactive bladder in children: a prospective open-label study. J Urol 197:1158–1163. https://doi.org/10.1016/j.juro.2016.11.101

    Article  PubMed  Google Scholar 

  17. Babu R. Effectiveness of tolterodine in non-neurogenic voiding dysfunction. Indian Pediatr 2006;43.

  18. Rittig S, Baka-Ostrowska M, Tøndel C, Walle J Vande, Kjaeer B, Passier P, et al. The pharmacokinetics, safety, and tolerability of mirabegron in children and adolescents with neurogenic detrusor overactivity or idiopathic overactive bladder and development of a population pharmacokinetic model–based pediatric dose estimation. J Pediatr Urol 2020;16:31.e1–31.e10. https://doi.org/10.1016/j.jpurol.2019.10.009.

  19. Misseri R, Combs AJ, Horowitz M, Donohoe JM, Glassberg KI. Myogenic failure in posterior urethral valve disease: real or imagined? J Urol 2002;168:1844–8; discussion 1848. https://doi.org/10.1097/01.ju.0000029633.06239.b7.

Download references

Funding

Nil.

Author information

Authors and Affiliations

  1. Department of Pediatric Urology, Sri Ramachandra Medical College and Research Institute, Porur, Chennai, Tamil Nadu, 600116, India

    Ramesh Babu, Thiyagarajan Chittibabu & Sugandh Chadha

Authors
  1. Ramesh Babu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thiyagarajan Chittibabu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Sugandh Chadha
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ramesh Babu.

Ethics declarations

Conflict of interest

Nil.

Ethical approval

IRB no. IEC/20/OCT/159/38.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Babu, R., Chittibabu, T. & Chadha, S. Safety and short-term efficacy of mirabegron in children with valve bladder: a pilot study. Pediatr Surg Int 38, 493–498 (2022). https://doi.org/10.1007/s00383-021-05040-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00383-021-05040-8

Keywords

Search

Navigation